Literature DB >> 20635135

Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.

Christina Justenhoven1, Elke Schaeffeler, Stefan Winter, Christian Baisch, Ute Hamann, Volker Harth, Sylvia Rabstein, Anne Spickenheuer, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Matthias Schwab, Hiltrud Brauch.   

Abstract

Organic anion transporter polypeptides (OATPs, SLCOs) are involved in the uptake of conjugates steroid hormones such as estrone-3-sulfate. It has been suggested that the expression of OATPs in breast tissues could impact breast carcinogenesis and tumor pathology. The nuclear receptor pregnane X receptor (PXR) is involved in the regulation of SLCO1A2 expression. We investigated 31 variants located in PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 for an association with breast cancer risk and/or histo-pathological tumor characteristics. Polymorphisms were selected on the basis of a known or potential functional consequence and an allele frequency >2%. Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the GENICA population-based breast cancer case-control collection comprising 1,021 cases and 1,015 age-matched controls. Statistical analysis was performed by SAS, and all tests were two-sided. None of the 31 analyzed transporter and PXR polymorphisms showed an association with breast cancer risk or tumor characteristics. Our data suggest that among the many known transporters common variations of PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 do not contribute to breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20635135     DOI: 10.1007/s10549-010-1046-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

Review 1.  Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression.

Authors:  Eunpi Cho; R Bruce Montgomery; Elahe A Mostaghel
Journal:  Endocrinology       Date:  2014-08-22       Impact factor: 4.736

2.  Pregnane X Receptor and Cancer: Context-Specificity is Key.

Authors:  Satyanarayana R Pondugula; Petr Pavek; Sridhar Mani
Journal:  Nucl Receptor Res       Date:  2016-06-12

3.  Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.

Authors:  Veronika Buxhofer-Ausch; Lena Secky; Katrin Wlcek; Martin Svoboda; Valentinos Kounnis; Evangelos Briasoulis; Andreas G Tzakos; Walter Jaeger; Theresia Thalhammer
Journal:  J Drug Deliv       Date:  2013-02-03

4.  Expression of OATP family members in hormone-related cancers: potential markers of progression.

Authors:  Heather Pressler; Tristan M Sissung; David Venzon; Douglas K Price; William D Figg
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

5.  Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy.

Authors:  Xuefeng Zhang; Zhichen Pu; Jun Ge; Jie Shen; Xiaolong Yuan; Haitang Xie
Journal:  Med Sci Monit       Date:  2015-02-21

6.  Association between PXR polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Jing Wen; Zhi Lv; Hanxi Ding; Xinxin Fang; Mingjun Sun
Journal:  Biosci Rep       Date:  2018-06-12       Impact factor: 3.840

Review 7.  Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis.

Authors:  Rachel Sutherland; Annette Meeson; Simon Lowes
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 8.  Associations between Pregnane X Receptor and Breast Cancer Growth and Progression.

Authors:  Bradley A Creamer; Shelly N B Sloan; Jennifer F Dennis; Robert Rogers; Sidney Spencer; Andrew McCuen; Purnadeo Persaud; Jeff L Staudinger
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

9.  Highly expressed SLCO1B3 inhibits the occurrence and development of breast cancer and can be used as a clinical indicator of prognosis.

Authors:  Tiantian Tang; Guiying Wang; Sihua Liu; Zhaoxue Zhang; Chen Liu; Fang Li; Xudi Liu; Lingjiao Meng; Huichai Yang; Chunxiao Li; Meixiang Sang; Lianmei Zhao
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

10.  The UGT1A6_19_GG genotype is a breast cancer risk factor.

Authors:  Christina Justenhoven; Ofure Obazee; Stefan Winter; Sylvia Rabstein; Anne Lotz; Volker Harth; Beate Pesch; Thomas Brüning; Christian Baisch; Jaana M Hartikainen; Arto Mannermaa; Veli-Matti Kosma; Vesa Kataja; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Peter A Fasching; Matthias Beckmann; Arif B Ekici; Alexander Hein; Per Hall; Jingmei Li; Jenny Chang-Claude; Dieter Flesch-Janys; Petra Seibold; Anja Rudolph; Ute Hamann; Yon-Dschun Ko; Hiltrud Brauch
Journal:  Front Genet       Date:  2013-06-11       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.